Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue	$ 8,194	$ 6,234	$ 19,462	$ 19,998
Cost of revenue	6,359	4,636	15,158	14,579
Gross profit	1,835	1,598	4,304	5,419
Operating expenses
Research and development	644	704	2,055	1,865
Selling	423	434	1,268	1,281
General and administrative	1,316	1,450	4,057	4,410
Gain on sale of equipment-Note 11	(625)		(625)
Loss on disposition of Tantaline				162
Impairment charge				111
Total operating expenses, net	1,758	2,588	6,755	7,829
Operating income (loss)	77	(990)	(2,451)	(2,410)
Other income (expense):
Interest income	136	173	438	400
Interest expense	(5)	(6)	(14)	(18)
Foreign exchange income				42
Other income		70	2	91
Total other income, net	131	237	426	515
Income (loss) before income tax	208	(753)	(2,025)	(1,895)
Income tax expense	5		5	11
Net income (loss)	$ 203	$ (753)	$ (2,030)	$ (1,906)
Income (loss) per common share - basic	$ 0.03	$ (0.11)	$ (0.30)	$ (0.28)
Income (loss) per common share - diluted	$ 0.03	$ (0.11)	$ (0.30)	$ (0.28)
Weighted average common shares
Basic	6,825,495	6,789,487	6,817,220	6,787,415
Diluted	6,834,627	6,789,487	6,817,220	6,787,415